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.2013.03Abstract HIV is a leading cause of mortality in resource limited settings and HIV associated med-
ical emergencies are common emergency centre presentations in high-prevalence settings. HIV
attacks the body’s immune system, making infected individuals susceptible to severe infections of
multiple organ systems including the respiratory tract, ocular structures, and central nervous sys-
tem. HIV infected individuals also suffer from unique patterns of cardiac disease, gastrointestinal
disturbances, and haematologic and oncologic conditions. Anti-retroviral therapy itself is also asso-
ciated with numerous side effects, many of which can be life-threatening. Diagnosis and manage-
ment of HIV infected patients require knowledge of the disease’s pathology and the life
threatening complications associated with it. Part 1 of this review discusses the pathophysiology
of the disease and respiratory, cardiac, psychiatric, and neurologic complications.
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IRISimmunitaire, rendant les individus infecte´s re´ceptifs a` de graves infections de multiples organes, tels
que les voies respiratoires, les structures oculaires et le syste`me nerveux central. Les personnes se´r-
opositives souffrent e´galement de types de maladies cardiaques uniques, de troubles gastro-intestin-
aux et de troubles he´matologiques et oncologiques. La the´rapie antire´trovirale est elle-meˆme
associe´e a` nombre d’effets secondaires, dont beaucoup peuvent s’ave´rer mortels. Le diagnostic et
la prise en charge des patients se´ropositifs ne´cessitent une bonne connaissance de la pathologie
de la maladie et des complications mortelles qui y sont associe´es. La premie`re partie de cet article
de synthe`se traite de la pathophysiologie de la maladie et de ses complications respiratoires, cardia-
ques, psychiatriques et neurologiques.
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 HIV is a major cause of mortality in Sub-Saharan Africa.
 Patients with HIV associated emergencies often present to
African emergency centres with acute illnesses.
 Patients may be naive to their own infection, their CD4
count, or their speciﬁc HAART regimen, so clinicians
require a broad knowledge base to manage these
presentations.
 As HAART becomes more widely available across the con-
tinent, complications of treatment will become an increas-
ingly common issue.
What’s new?
 HIV infected patients present to emergency centres with a
wide variety of acute presentations associated with their
disease.
 Managing HIV emergencies requires an understanding of
the virus pathophysiology.
 Antiretroviral therapy is also associated with numerous
complications that can present as acute illness.
Introduction
Addressing the HIV/AIDS pandemic has been the leading glo-
bal health challenge of the past two decades. Although its
scope has been global, the disease has been particularly devas-
tating in the African continent. Despite the increasing avail-
ability of highly active antiretroviral therapy (HAART), the
disease remains the leading cause of death across many coun-
tries in Sub-Saharan Africa. According to UNAIDS, the re-
gion has over 22.5 million individuals infected with HIV,
68% of the global total.1 In Southern Africa, which includes
several countries with the world’s highest prevalence of HIV,
an estimated 610,000 people died of the disease in 2009.1
The emergency centre (EC) is an important point of diagno-
sis of new infections and care for conditions related to those
infections. The impact and epidemiology of HIV/AIDS-related
medical emergencies presenting to ECs across Africa is un-
known, but can be assumed to be country speciﬁc. It is dictatedby the national prevalence of HIV, the availability of HAART,
and the expertise of the primary health system. A prospective
study in Cote d’Ivoire in 1999, for example, categorized 312
HIV-related presentations to an EC as general deteriorations
in health (62%), diarrhoea (39.1%), and cough (20.5%) as
the leading chief complaints, with 84% noting severe weight
loss and 50% noting fever.2
HIV-positive patients are susceptible to a variety of life-
threatening conditions including tuberculosis, bacterial pneu-
monia, meningitis, diarrhoea, malignancies, and a wide spec-
trum of medication side effects. This clinical review will
describe approaches to HIV-positive patients presenting with
medical emergencies related to their infection. Part 1 will dis-
cuss the pathophysiology of HIV and AIDS and associated
respiratory, cardiac, psychiatric, and neurologic complica-
tions. Part 2 will cover haematologic/oncologic, ocular, gastro-
intestinal, and treatment complications.
Pathophysiology
HIV, an RNA retrovirus, targets host immune defences by
infecting and eventually destroying CD4 cells. CD4 cells are
central players in both humoral and cell-mediated immunity.3
With continued HIV replication, CD4 cells progressively de-
cline and increase susceptibility to opportunistic infections
(OI). OIs are caused by infectious pathogens which do not nor-
mally cause disease in immuno-competent hosts and represent
the leading cause of death among patients with AIDS around
the world.
Acute retroviral syndrome (ARS) occurs approximately 2–
3 weeks following HIV transmission. At this stage of HIV
infection, antibody formation has not yet occurred resulting
in very high HIV viral loads. Symptoms are variable from a
ﬂu-like illness to overt aseptic meningitis. Most common
symptoms include fever, lymphadenopathy, pharyngitis and
rash.4 Recognition of ARS is important for many reasons.
Firstly, newly infected individuals are highly infectious during
ARS and knowledge of HIV status may trigger behavioural
changes that can prevent further transmissions. Furthermore,
traditional HIV antibody testing will be falsely negative neces-
sitating a high index of clinical suspicion to check an HIV viral
load for diagnosis. Lastly, though the symptoms can be vari-
able, most patients with ARS are symptomatic, providing
opportunities for diagnosis and linkage to care.
According to the World Health Organization, AIDS is de-
ﬁned as the presence of WHO stage IV AIDS-related condition
144 A. Chandra et al.shown in Table 1. The overall morbidity and mortality for
AIDS is unacceptably high without effective HAART. Though
the average clinical progression to AIDS occurs approximately
7–10 years following initial infection, the majority of patients
are diagnosed with HIV after progression to AIDS.5 In re-
source-limited settings, patients presenting to ECs may be una-
ware of their HIV status and are likely to present with AIDS-
related conditions.
Respiratory
Respiratory complaints are common presenting symptoms in
HIV infected patients presenting to health facilities, and are of-
ten the presenting complaint of patients not yet diagnosed with
HIV. A good general approach to respiratory complaints in
the EC includes a thorough physical exam, a chest X-ray, pulse
oximetry, and blood and sputum investigations including ser-
um LDH, blood cultures, sputum microscopy, and sputum
culture for bacterial (including TB) and fungal organisms. It
is also important to obtain a detailed history, as not all respi-
ratory illnesses are due to infection, and some respiratory com-
plaints may be due to systemic or oncologic causes such as
lung cancer, lymphoma, or Kaposi’s sarcoma. If the patient’s
CD4 count is known, it can be helpful in isolating the most
likely cause of the patient’s symptoms. Patients presenting withTable 1 WHO clinical staging of HIV in adults and adolescents.
Primary HIV infection
Asymptomatic
 Acute retroviral syndrome
Clinical stage 1
Asymptomatic
 Persistent generalized lymphadenopathy
Clinical stage 2
 Moderate unexplained weight loss
 Recurrent respiratory infections
 Herpes Zoster
 Angular cheilitis
Clinical stage 3
 Unexplained severe weight loss
 Unexplained chronic diarrhoea for >1 month
 Unexplained persistent fever for >1 month
 Persistent oral candidiasis
 Oral hairy leukoplakia
 Pulmonary Tuberculosis
Clinical stage 4
 HIV Wasting syndrome
 Pneumocystis pneumonia
 Recurrent severe bacterial pneumonia
 Chronic herpes simplex infection
 Oesophageal candidiasis
 Extra-pulmonary Tuberculosis
 Kaposi Sarcoma
 Cytomegalovirus
 Central Nervous system toxoplasmosis
 HIV Encephalopathy
 Extra-pulmonary Cryptococcus
 Disseminated non-tuberculosis mycobacterial infection
 Progressive multifocal leukoencephalopathy
Source: World Health Organization. WHO case deﬁnitions of HIV for sur
of HIV-related disease in adults and children; 2007. Available at http://wsigniﬁcant respiratory symptoms who are suspected of having
a low CD4 count should be hospitalized and immediately
started on treatment for bacterial pneumonia while awaiting
deﬁnitive results. Patients with severe respiratory distress,
low oxygen saturations, and diffuse crackles on examination
should be considered as Pneumocystis jiroveci pneumonia
(PCP) suspects and started on PCP therapy as soon as
possible.
Bacterial pneumonia
While HIV patients are at risk of illness due to opportunistic
pathogens, they are also at high risk of severe illness due to
the same organisms that cause infections in immune-compe-
tent individuals. HIV infected persons who are not on
HAART have a 5 to 25-fold higher rate of bacterial pneumo-
nia compared to uninfected persons and recurrent severe bac-
terial pneumonia (P2 episodes within 12 months) is
considered a WHO clinical stage four diagnosis.6 Streptococ-
cus pneumoniae is the leading bacterial cause of community-ac-
quired pneumonia in adults, particularly those who have not
been vaccinated. New urinary antigen tests for S. pneumoniae
show promise by allowing for rapid diagnosis, particularly in
patients with pneumonia and bacteremia.7 Other potential
causes include gram negatives like Haemophilus inﬂuenzae, Recurrent oral ulceration
 Papular pruritic eruptions
 Seborrhoeic dermatitis
 Fungal nail infections
 Severe presumed bacterial infections
 Acute necrotizing ulcerative stomatitis, gingivitis or peridontitis
 Unexplained anaemia
 Neutropenia
 Chronic Thrombocytopenia
 Candida of trachea, bronchi or lungs
 Chronic cryptosporidiosis
 Chronic isosporiasis
 Disseminated mycosis
 Recurrent nontyphoidal Salmonella bacteraemia
 Lymphoma
 Invasive cervical cancer
 Atypical disseminated leishmaniasis
 Symptomatic HIV-associated nephropathy
 Symptomatic HIV-associated cardiomyopathy
 Reactivation of American trypanosomiasis
veillance and revised clinical staging and immunological classiﬁcation
ww.who.int/hiv/pub/guidelines/HIVstaging150307.pdf.
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such as Mycoplasma pneumoniae, Chlamydophila (Chlamydia)
pneumoniae and Legionella pneumophila, and even community-
acquired Staphylococcus aureus.8 At lower CD4 counts, atypi-
cal causes can include P. jiroveci, Cryptococcus neoformans,
Pseudomonas aeruginosa, Toxoplasma gondii, Histoplasma cap-
sulatum, Chlamydia immitis, Cytomegalovirus, Mycobacterium
avium complex, and aspergillus species.9 Tuberculosis should
also be kept in mind, as TB may present atypically as a lobar
pneumonia, especially in the lower lobes.10
The best empiric treatment for presumed bacterial pneumo-
nia in an HIV-infected adult therefore includes a b-lactam
(preferably a second or third generation cephalosporin if avail-
able, or cloxacillin if S. aureus is diagnosed or strongly sus-
pected) and a macrolide or doxycycline to cover for
atypicals. In high prevalence tuberculosis (TB) areas ﬂuoro-
quinolones should be avoided due to the concerns both in
masking tuberculosis infection as well as creating resistance.
Clinicians must also keep in mind that HIV infected persons
may have more than one infection causing illness upon presen-
tation to the EC, and consideration should be given to starting
all appropriate therapy and then narrowing the therapy as
more information becomes available. Nosocomial pneumonias
are also frequent, especially in those with lower CD4 counts.
Coverage with broader spectrum antibiotics should be consid-
ered for any patients who have recently been discharged from
the hospital, as increasing rates of P. aeruginosa, methicillin-
resistant S. aureus, and even extended spectrum beta-lactamase
(ESBL) producing K. pneumoniae have been described in HIV-
infected patients with nosocomial bacterial pneumonias.11,12
The addition of vancomycin may be considered if methicil-
lin-resistant staphylococcus or extensively-resistant S. pneumo-
niae are suspected, and carbapenems (imipenem, meropenem)
should be given if ESBL organisms are diagnosed or strongly
suspected, especially if the patient has recently received a third
generation cephalosporin (ceftriaxone, cefotaxime, and
ceftazidime).
Pneumocystis jiroveci pneumonia (PCP)
The second most common respiratory infection in HIV-in-
fected patients, and potentially occurring concomitantly with
bacterial pneumonia and TB, is PCP.13 The classic presenta-
tion of PCP includes non-productive cough with progressive
dyspnoea, particularly when ambulating, fevers, a chest X-
ray with bilateral ground glass opacities but without distinct
lobar opacities, and a serum LDH level >500 mg/dL.14 Aus-
cultation of the lungs may be normal or may reveal crackles
out of proportion to the ﬁndings on the chest X-ray. If a chest
X-ray or oxygen saturation levels are unavailable or unreliable,
a serum LDH elevated above 500 may support a clinical suspi-
cion of PCP in a patient with signiﬁcant respiratory distress. In
the era prior to HAART therapy and routine PCP prophy-
laxis, 24% of HIV-infected persons with CD4 counts
<200cells/mm3 would develop PCP within 12 months.15 Up
to 30% of PCP diagnoses are found in patients who are not
previously known to be infected with HIV.16 Fortunately,
PCP is both treatable and preventable. Intravenous trimetho-
prim/sulfamethoxazole (cotrimoxazole) remains the ﬁrst line
therapy for inpatient treatment of PCP pneumonia, although
cotrimoxazole tablets can be used via PO or NG if IV isunavailable.14 If hypoxia is present, denoted by signiﬁcant rest-
ing or ambulatory oxygen desaturations or PaO2 of
<70 mmHg on an arterial blood gas (ABG), steroids are rec-
ommended.14 Overall mortality rates for patients hospitalized
for PCP pneumonia have decreased to 11.6% in resource-rich
settings, although patients requiring ICU admission have a
mortality rate of approximately 30% regardless of HAART
therapy.17 Clinicians must be alert for signs of pneumothorax
in patients with PCP, as 5–9% percent of patients with PCP
will develop pneumothoraces due to the rupture of pneumato-
celes caused by the infection.18
International guidelines recommend PCP prophylaxis with
cotrimoxazole (or dapsone or aerosolized pentamidine if
cotrimoxazole is not tolerated) for all patients with CD4
counts <200 and state that prophylaxis can be discontinued
if a patient on HAART has a CD4 count consistently above
200 for at least 6 months.14 Recent studies from developed
countries have suggested that prophylaxis may be discontin-
ued for patients with CD4 counts <200 with virological sup-
pression, however data from Asia indicate that patients with
CD4 <200 (94% of whom were on antiretroviral therapy)
not on PCP prophylaxis had 10-fold higher mortality rates
than those on prophylaxis, and they even noted an overall
mortality beneﬁt in patients with CD4 >200.19,20 Cotrimox-
azole also exerts protective effects against a wide variety of
bacterial and protozoal infections, and may improve out-
comes based on preventing these illnesses in addition to
PCP.
Pulmonary tuberculosis
At least one-third of the 34 million people with HIV are also
infected with Mycobacterium tuberculosis (TB), and it is the
leading cause of death among HIV patients.21 Pulmonary TB
should be suspected in any HIV infected patient presenting
to the A&E with respiratory symptoms, particularly if the pa-
tient reports recent weight loss, night sweats or fevers, and
contact with others who have been coughing. Studies have
demonstrated that the length of the cough is misleading in
HIV infected patients, as both acute and chronic (>2 weeks)
cough are associated with similar odds ratios for TB.22 Partic-
ular attention should be paid to patients with a history of a TB
diagnosis in the past, as they may be at higher risk for multi-
drug resistant (MDR) TB. Additionally, if the patient was re-
cently started on HAART therapy and then developed symp-
toms, clinicians should have a high suspicion for TB-
associated immune reconstitution inﬂammatory syndrome
(IRIS). Patients with symptoms concerning TB should be
admitted to an area of the hospital with appropriate isolation
facilities while awaiting conﬁrmation of the diagnosis. Severely
ill HIV infected patients with symptoms concerning for tuber-
culosis should have an acid fast bacilli (AFB) smear and cul-
ture sent as soon as possible. If available GeneXpert testing
should be done as the ﬁrst test for all HIV-infected patients
suspected of having pulmonary TB and any patients in whom
drug-resistant TB is suspected, per WHO recommenda-
tions.23,24 New urinary tests for bedside diagnosis of TB are
in development and appear to be particularly useful for indi-
viduals with CD4 counts <100cells/mm3.25
Emergency clinicians should keep in mind that 24–61%
percent of HIV-infected patients with active pulmonary tuber-
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nated tuberculosis.26 Also, 4–40% percent of HIV-infected pa-
tients with tuberculosis will have extra-pulmonary TB (EPTB),
which may include pleural effusions, pericardial effusions,
abdominal TB, and signiﬁcant lymphadenopathy.26 These
forms of EPTB may lead to respiratory symptoms without
the classic presentation of cavitating disease on X-ray and
AFBs on smear.
Asthma and chronic lung disease
Although the mechanism is not well understood, it appears
that HIV-infected persons have higher rates of bronchial hy-
per-responsiveness and elevations of IgE consistent with the
diagnosis of asthma and higher rates of COPD than HIV
sero-negative persons, even in the era of HAART treatment.27
Patients with prior histories of tuberculosis also have high
rates of chronic pulmonary disease, even after treatment, due
to irreversible lung damage. Thus, consideration should also
be given to possible non-infectious causes of respiratory dis-
tress in HIV infected persons, and treatment should be at-
tempted with b-agonist medications if clinically indicated.28
Mechanical ventilation
In the pre-HAART era, the prognosis for HIV patients was
considered to be so poor that mechanical ventilation of se-
verely ill patients was generally discouraged. However, with
the availability of HAART therapy and the improved under-
standing of the disease processes leading to respiratory distress
in HIV infected persons, survival rates for HIV-infected per-
sons admitted to ICU have improved substantially, up to
61–80% in high resource settings.29 Recent data also indicate
that successful extubation rates are similar between HIV-in-
fected and uninfected patients.30 Intubation and mechanical
ventilation, if available, should therefore be considered for pa-
tients with respiratory failure, regardless of their HIV status.
Cardiac
Cardiovascular disease has been noted to be on the rise among
HIV infected patients, especially in the context of longer life
spans associated with HAART.31
Coronary artery disease
HIV infection independently predisposes individuals towards
coronary artery disease via a combination of a heightened
inﬂammatory state, endothelial dysfunction, hyperlipidaemia,
and thrombosis.32,33 Similarly, protease inhibitor (PI) therapy
has been known to exacerbate the aforementioned responses,
particularly during prolonged treatment.33 Several studies
have found rising rates of acute myocardial infarctions follow-
ing the introduction of PIs and increased exposure to
HAART.34 Any middle aged HIV positive patient with suspi-
cious symptoms should be screened for an acute coronary syn-
drome (ACS). Thrombolysis, percutaneous coronary
intervention with and without stenting, and coronary artery
bypass grafting are feasible in the setting of ACS, regardless
of HIV infection, where resources permit.34Pericardial disease
Pericarditis is on the rise in Sub-Saharan Africa as a result of
the HIV epidemic.35 Tuberculosis is the aetiologic cause of
large pericardial effusions in more than 90% of HIV infected
patients living in tuberculosis-endemic regions.35 Other causes
of pericardial effusions include congestive cardiac failure
(CCF), Kaposi’s sarcoma and bacterial infections such as S.
pneumonia and S. aureus.34,36 Patients with HIV are more
likely to present with dyspnoea, oedema and ECG changes
consistent with myopericarditis.35 Pericardiocentesis is neces-
sary for large symptomatic effusions, to obtain specimens for
diagnostic investigation, and to reverse the effects of an acute
cardiac tamponade. The role of adjuvant steroids in tubercu-
lous pericardial effusions remains unclear, especially in the
HIV population.37
Cardiomyopathy
Several studies performed prior to the advent of HAART dem-
onstrated that HIV is an important aetiologic factor of dilated
cardiomyopathy.38–40 HIV associated cardiomyopathy leads to
diminished systolic function often associated with left ventric-
ular dilatation.35 Dilated cardiomyopathy is estimated at 15–
17% in Sub-Saharan Africa, with similar values of approxi-
mately 15% globally.38,41 Myocarditis is a well-studied cause
of dilated cardiomyopathy in HIV patients, which can be
attributed to T. gondii, C. neoformans, M. avium intracellulare
and to the HIV infection itself.39 It is important to suspect
acute myocarditis in HIV patients, as the condition may pro-
gress to life-threatening CCF and fatal arrhythmias. The dis-
ease may begin with symptoms of fever, infection of the
upper respiratory tract, or a ﬂu-like syndrome, and lead to
exertional dyspnoea over hours or days. Progressive signs
and symptoms include palpitations, chest pain, ECG changes,
and elevated cardiac enzymes. Standard treatment for heart
failure should be initiated to manage patients with HIV-asso-
ciated cardiomyopathy.42Psychiatric
Neuropsychiatric conditions occur in HIV patients more often
than the general population. These conditions include depres-
sion, anxiety, substance and alcohol abuse.5 Though the wors-
ening of underlying conditions may prompt patients to seek
care in the EC, organic causes such as CNS infection, malig-
nancy or medication side effects should be on the differential.Neurologic
Neurologic complications in HIV-infected individuals vary
from opportunistic infections to neurocognitive disorders.
HIV-associated neurocognitive defects (HAND) represent a
clinical spectrum including HIV-associated asymptomatic neu-
rocognitive impairment (ANI), HIV-associated mild neurocog-
nitive disorder (MND) and HIV-associated dementia
(HAD).43 Though HAD is characteristic of overt dementia
and impairment of daily functioning, milder forms persist
which may be more difﬁcult to diagnose. Patients with HAND
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ing a systemic infection.
Neurologic complications of HIV manifest in 75–90% of
AIDS patients.4 Neurologic symptoms including headache,
seizure, altered mental status or focal neurologic deﬁcits in
these patients should initiate an evaluation for an underling
OI.44 The lumbar puncture (LP) can be a lifesaving diagnostic
and therapeutic procedure. Patients with focal neurologic def-
icits will require a CT scan (if available) ﬁrst to exclude the
presence of focal lesions.4 The most common HIV associated
central nervous system (CNS) conditions are cryptococcal
meningitis, toxoplasmosis, tuberculosis and lymphoma. Bacte-
rial meningitis should be on the differential and unless a deﬁn-
itive alternate diagnosis is made, it is reasonable to begin
empiric treatment while awaiting further results.
Cryptococcal meningitis
The incidence of cryptococcal meningitis in Sub-Saharan Afri-
ca is high and accounts for 10–20% of AIDS related deaths.45
Untreated cryptococcal meningitis carries a mortality of up to
100%.45 C. neoformans, a fungus, is the aetiologic agent caus-
ing meningoencephalitis.4 The typical presentation includes
subacute headache, fever, cranial nerve palsies or altered men-
tal status. Signs of meningeal irritation are only apparent in a
third of patients and the lack thereof should not exclude the
diagnosis.45 Though most apparent at CD4 <100, EC clini-
cians may not have the beneﬁt of this information and a high
index of suspicion should be maintained.
An LP should be performed as soon as possible and may
reveal a lymphocytic pleocytosis. The opening pressure (OP)
will be elevated in up to 75% of patients.46,47 The single most
important error in the management of these patients is the fail-
ure to manage OP.48 Goal reduction of OP is the removal of
up to 20 cm H2O or by 50%. Patients may require daily LPs
or in severe cases, placement of a ventriculo-peritoneal shunt.
Diagnosis can be conﬁrmed by cryptococcal antigen present
in the serum or cerebrospinal ﬂuid (CSF) with a sensitivity
>95%.49 Positive India ink stain occurs in 80% of individuals
with AIDS.49 Culture can be performed but there should be no
delay in the initiation of appropriate treatment. Though not
widely available at this time, a point of care lateral ﬂow cryp-
tococcal assay has been developed which may be able to im-
prove diagnosis in resource limited settings where LPs may
be refused or the capacity of laboratory analysis is limited.50
Treatment is typically divided into three phases: induction
(Ampho B + 5-ﬂucytosine), consolidation and maintenance
with high and low dose ﬂuconazole respectively. In resource-
limited settings, 5 ﬂucytosine may be unavailable and options
may include amphotericin B alone or in conjunction with high
dose ﬂuconazole for induction.
Toxoplasmosis
Toxoplasmosis is caused by the protozoan, T. gondii, and is the
most common cause of focal brain mass in HIV infected pa-
tients, particularly at CD4 levels <200.4,5 Typical presentation
is subacute with headache, fever, altered mentation, motor or
sensory focal neurologic deﬁcits and seizures. CT shows char-
acteristic multiple ring enhancing lesions. Serology for serumtoxoplasmosis antibody can be performed, though positive
serology does not differentiate between active disease and prior
exposure; negative serology however, makes toxoplasmosis
less likely. First line treatment includes pyrimethamine and sul-
fadiazine with folic acid. If ﬁrst line therapy is unavailable,
cotrimoxazole can be used. Clinical response to appropriate
treatment will dictate the need for further work-up. Over
90% of patients will respond after 2 weeks of treatment with
the majority responding after 5 days.5
Patients without clinical improvement may require evalua-
tion for primary CNS lymphoma (PCNSL) as symptoms and
CT ﬁndings can be indistinguishable. Biopsy remains the main-
stay of diagnosis for PCNSL.
TB meningitis
In patients with advanced immunosuppression, extra-pulmon-
ary TB can manifest as meningitis. TB meningitis can be debil-
itating and is associated with high levels of death and
disability. Symptoms are often non-speciﬁc including head-
ache, fever, cranial nerve palsies, seizures and altered menta-
tion, although classic meningeal symptoms can be present.
The duration of symptoms are usually >2 weeks though it
can also present acutely.51 Affected patients may also have
signs of spinal TB with paraplegia and spinal tenderness.
Tuberculomas can be clinically indistinguishable from brain
abscesses. In regions of high TB prevalence, tuberculosis
may be higher on the differential of space occupying lesions
than toxoplasmosis or malignancy and can occur at higher
CD4 cell strata.
The diagnosis of TB meningitis remains a clinical dilemma
as no rapid and effective point of care testing exists. Diagnosis
requires an LP with CSF examination usually revealing a lym-
phocytic pleocytosis with low glucose. CSF AFB has limited
sensitivity and culture yield is variable though both are im-
proved with large volume LPs.52 As 30–50% of patients with
TB meningitis have active pulmonary TB, chest radiograph,
sputum AFB and culture may aid in the diagnosis. Anti-tuber-
culous therapy should be promptly initiated along with the
consideration of steroid therapy.51
The second part of this clinical review will be published in
the next issue. It will discuss haematologic/oncologic, ocular,
gastrointestinal, and treatment complications.Acknowledgment
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